The FDA has granted a quick observe designation to SYNC-T SV-102, an investigational remedy for sufferers with metastatic castrate-resistant prostate most cancers (mCRPC),...
Merck & Co (MSD) has introduced that its ongoing settlement with Orion Company for the co-development and co-commercialisation of opevesostat (MK-5684/ODM-208) has modified...
The FDA has granted quick observe designation to SYNC-T SV-102 remedy (Syncromune Inc.) for the therapy of metastatic castration-resistant prostate most cancers (mCRPC)....
